FDA Warns that Vancomycin Eye Injections May Lead to Blindness

October 6, 2017: By Joan McKenna

1 Ophthalmic NewsVancomycin injections during eye surgery can lead to hemorrhagic occlusive retinal vasculitis (HORV), a rare, potentially blinding postoperative complication, the FDA warned Oct. 3 in a compounding risk alert to health care providers.

The agency said it received an adverse event report Aug. 14, 2017, for a patient who developed bilateral HORV after being administered injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation in each eye at the conclusion of cataract surgeries performed two weeks apart. The TMV formulation was compounded by Imprimis Pharmaceuticals at its outsourcing facility in Ledgewood, New Jersey.

The FDA said symptoms of HORV include a delayed onset of sudden painless decreased vision, intraocular inflammation, intraretinal hemorrhage, retinal vasculitis, vascular occlusion, and retinal ischemia.

At the 2016 AAO meeting, Dean Eliott, MD, said HORV is suspected to be a rare type III hypersensitivity to vancomycin, but its exact cause and pathogenesis remain unproven.

The FDA said many ophthalmologists use intraocular vancomycin during cataract surgery to prevent postoperative endophthalmitis.

The agency said there is no US-approved vancomycin formulation for intraocular injection, and it is unaware of any adequately controlled studies demonstrating the safety and efficacy of vancomycin in preventing endophthalmitis.

The formulation is usually prepared at the surgical site or obtained in advance of surgery from a compounding pharmacy.

The agency concluded that prophylactic use of vancomycin, alone or in a compounded combination drugs, during cataract surgery is generally not recommended due to the risk of HORV.

The FDA said that, if vancomycin is administered to both eyes, patients with HORV likely will wind up legally blind.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022